Fast Five Quiz: Are You Prepared to Confront Multiple Myeloma?

Emmanuel C Besa, MD; Dhaval Shah, MD


January 14, 2022

A triplet regimen is standard therapy for nontransplant patients with multiple myeloma. Patients who cannot tolerate a triplet regimen can be started on a doublet regimen. Currently, the use of quadruplet regimens is reserved for transplant-eligible patients with high-risk double- or triple-hit myeloma. The National Comprehensive Cancer Network (NCCN) guidelines for multiple myeloma list the following combinations as preferred regimens (category 1) for primary induction therapy in patients who are not transplant candidates:

  • Bortezomib/lenalidomide/dexamethasone

  • Daratumumab/lenalidomide/dexamethasone

Learn more about the treatment of multiple myeloma.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.